Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Common Equity (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Common Equity for 8 consecutive years, with $214.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 11.2% year-over-year to $214.0 million, compared with a TTM value of $214.0 million through Dec 2025, down 11.2%, and an annual FY2025 reading of $214.0 million, down 11.2% over the prior year.
  • Common Equity was $214.0 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $224.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $352.6 million in Q1 2021 and bottomed at $145.7 million in Q3 2022.
  • Average Common Equity over 5 years is $250.9 million, with a median of $258.9 million recorded in 2021.
  • The sharpest move saw Common Equity surged 1976.36% in 2021, then plummeted 47.6% in 2022.
  • Year by year, Common Equity stood at $228.2 million in 2021, then increased by 18.45% to $270.3 million in 2022, then rose by 3.03% to $278.5 million in 2023, then decreased by 13.48% to $241.0 million in 2024, then decreased by 11.2% to $214.0 million in 2025.
  • Business Quant data shows Common Equity for ARCT at $214.0 million in Q4 2025, $224.6 million in Q3 2025, and $231.1 million in Q2 2025.